The effect of insulin degludec in combination with liraglutide and metformin in patients with type 2 diabetes requiring treatment intensification

被引：0
|
作者：
Aroda, V. R. [1 ]
Bailey, T. [2 ]
Cariou, B. [3 ]
Kumar, S. [4 ,5 ]
Leiter, L. A. [6 ]
Raskin, P. [7 ]
Zacho, J. [8 ]
Bandier, M. [8 ]
Philis-Tsimikas, A. [9 ]
机构：
[1] MedStar Hlth Res Inst, Hyattsville, MD USA
[2] AMCR Inst Inc, Escondido, CA USA
[3] Nantes Univ Hosp, Dept Endocrinol, Nantes, France
[4] Univ Hosp Coventry, WISDEM Ctr, Coventry, W Midlands, England
[5] Univ Hosp Warwickshire, WISDEM Ctr, Coventry, W Midlands, England
[6] Univ Toronto, St Michaels Hosp, Toronto, ON M5S 1A1, Canada
[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[8] Novo Nordisk AS, Soborg, Denmark
[9] Scripps Whittier Diabet Inst, San Diego, CA USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
145
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [21] Liraglutide in Combination with Insulin Therapy in Patients with Type 2 Diabetes
    Kern, W.
    DIABETES STOFFWECHSEL UND HERZ, 2016, 25 (02): : 95 - 101
  • [22] Postprandial glycaemic control in patients with Type 2 diabetes on a combination of insulin degludec and liraglutide vs each component individually
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Linjawi, S.
    Poulsen, P.
    Damgaard, L. H.
    Bode, B. W.
    DIABETIC MEDICINE, 2014, 31 : 51 - 51
  • [23] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Heo, Young-A
    DRUGS & THERAPY PERSPECTIVES, 2020, 36 (06) : 219 - 229
  • [24] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Young-A Heo
    Drugs & Therapy Perspectives, 2020, 36 : 219 - 229
  • [25] Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1529): : 147 - 149
  • [26] IDegLira, a combination of insulin degludec and liraglutide, is efficacious across the range of disease progression in Type 2 diabetes
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Langbakke, I. H.
    Korsholm, L.
    Vilsboll, T.
    DIABETIC MEDICINE, 2015, 32 : 75 - 75
  • [27] Triglyceride Reduction and Effect on Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus Receiving Fixed-Dose Combination of Insulin Degludec and Liraglutide
    Pappa, Eleni
    Kostara, Christina
    Dimou, Aikaterini
    Bairaktari, Eleni T.
    Tsimihodimos, Vasilis
    DIABETES, 2021, 70
  • [28] The Effect of Combination Therapy of Degludec and Liraglutide in Hospitalized Patients with Uncontrolled Type 2 Diabetes (T2DM)
    Akiyama, Tomoaki
    Yamada, Masayo
    Katsuragawa, Sho
    Terui, Sakiko
    Minami, Taichi
    Terauchi, Yasuo
    DIABETES, 2017, 66 : A295 - A295
  • [29] The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes
    Harris, Kira
    Nealy, Kimberly Lovin
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (01) : 69 - 77
  • [30] Evaluation of the CGMs in type-2 diabetic patients switched from Liraglutide and Insulin Degludec to Liraglutide and Insulin Degludec/Aspart
    Kakizaki, Yusuke
    Fujita, Tomoko
    Takahashi, Tomono
    Miwa, Takashi
    Odawara, Masato
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S111 - S111
12345